E
Zentalis Pharmaceuticals, Inc. ZNTL
$4.16 $0.061.46%
Recommendation
Sell
Prev Close
$4.10
Volume
2,493,455
Avg Vol (90D)
1,782,138
Market Cap
$291.54M
Dividend & Yield
--
52-Week Range
$2.83 - $23.52
P/E (TTM)
--
EPS (TTM)
-$2.75
My Lists My Alerts
Report
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Zentalis Pharmaceuticals (ZNTL, $4.1) RSI Indicator left the overbought zone on September 17, 2024
9/18/2024 - Tickeron - Stocks
Zentalis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ZNTL)
9/18/2024 - Zolmax
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $11.33 Consensus Target Price from Brokerages
9/18/2024 - Ticker Report
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
9/17/2024 - Zacks Investment Research
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Reaffirmed by Oppenheimer
9/17/2024 - Ticker Report
Stock Traders Purchase High Volume of Zentalis Pharmaceuticals Call Options (NASDAQ:ZNTL)
9/17/2024 - Ticker Report
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
9/17/2024 - PR Newswire
Notable Monday Option Activity: ZNTL, JEF, SWKS
9/16/2024 - Stock Options Channel
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
9/16/2024 - Benzinga
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
9/16/2024 - Globe Newswire
Los Angeles Capital Management LLC Has $342,000 Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)
9/15/2024 - Zolmax
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of "Hold" from Analysts
9/15/2024 - Ticker Report
Zentalis Pharmaceuticals (ZNTL, $3.24) entered Downtrend as Momentum indicator drops below 0 level on Sep 13, 2024
9/14/2024 - Tickeron - Stocks
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank
9/11/2024 - Ticker Report
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
9/9/2024 - Globe Newswire
Zentalis Pharmaceuticals (ZNTL, $3.24) entered Downtrend as Momentum indicator drops below 0 level on Sep 05, 2024
9/6/2024 - Tickeron - Stocks
Zentalis Pharmaceuticals (ZNTL, $3.23) entered Downtrend as Momentum indicator drops below 0 level on Sep 03, 2024
9/4/2024 - Tickeron - Stocks
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/3/2024 - Globe Newswire
14,152 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Purchased by SG Americas Securities LLC
8/28/2024 - Ticker Report
Commit To Buy Zentalis Pharmaceuticals At $2.50, Earn 22% Annualized Using Options
8/28/2024 - Stock Options Channel
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
8/26/2024 - Zacks Investment Research
Zentalis Pharmaceuticals (ZNTL, $3.19) Aroon Indicator entered a Downtrend on August 23, 2024.
8/24/2024 - Tickeron - Technical Analysis
Zentalis Pharmaceuticals (ZNTL, $3.07) Aroon Indicator entered a Downtrend on August 22, 2024.
8/23/2024 - Tickeron - Stocks
Zentalis Pharmaceuticals (ZNTL, $3.07) entered Downtrend as Momentum indicator drops below 0 level on Aug 22, 2024
8/23/2024 - Tickeron - Stocks
Zentalis Pharmaceuticals (ZNTL, $3.3) Aroon Indicator entered a Downtrend on August 21, 2024.
8/22/2024 - Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
$40.56M
EBITDA (TTM)
-$219.22M
EBIT (TTM)
-$220.55M
Net Income (TTM)
-$194.65M
Balance Sheet
Total Assets (Q)
$491.68M
Total Debt (Q)
$44.03M
Total Liabilities (Q)
$109.10M
Book Value Per Share (Q)
$5.38
Cash Flow
Cash from Operations (TTM)
-$166.38M
Cash from Investing (TTM)
-$63.48M
Cash from Financing (TTM)
$325.00K
Net Change in Cash (TTM)
-$229.53M
Filings
Filing Date
Friday, August 9, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Week of Nov 4 and 8 (est)
Price History
Loading...
Beta
1.25
7-Day Total Return
37.29%
30-Day Total Return
18.18%
60-Day Total Return
-9.57%
90-Day Total Return
-66.77%
Year to Date Total Return
-73.98%
1-Year Total Return
-81.50%
2-Year Total Return
-81.85%
3-Year Total Return
-93.60%
5-Year Total Return
--
52-week Low
Aug 14, 2024 - $2.83
52-week High
Sep 18, 2023 - $23.52
Valuation
Market Cap
$291.54M - Micro Cap
Enterprise Value
-$90.82M
Price/Sales (TTM)
7.18
Price/Book (Q)
0.76
Dividends and Shares
Shares Outstanding
71.04M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
zentalis.com
Phone Number
212 433 3791
Address
1359 Broadway
New York, NY 10018
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products... more
NASDAQ 09/18/2024 4:00PM Eastern Quotes delayed
Weiss Ratings